1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
67AC239C0944739866525804B00209BF9
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-developing-strong-medical-information-groups-compliance-activities-resource-levels?opendocument
18
19opendocument
203.227.208.153
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Communication

Developing Strong Medical Information Groups: Compliance, Activities & Resource Levels

ID: 5431


Features:

9 Info Graphics

12 Data Graphics

120 Metrics

2 Narratives


Pages/Slides: 29


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Developing Strong Medical Information Groups: Compliance, Activities & Resource Levels”

STUDY OVERVIEW

Medical information groups within biopharmaceutical companies are responsible for the management of publications and product inquiries during commercialization. Considering the stringent regulations in the industry, medical affairs leaders must ensure that their medical information activities are aligned with compliance requirements.

Best Practices, LLC undertook benchmarking research to explore how leading pharma and biotech companies structure and resource their medical information groups. The study delivers benchmarks around alignment of information activities with compliance requirements and requisite resource levels to create successful medical information groups.


KEY TOPICS

  • Structure and Leadership of Medical Information Groups
  • Compliance Guidelines and Information Sharing
  • Medical Information Activities
  • Case Example: Development of Self-Service Portal for Health Care Providers (HCPs)
  • Resource Benchmarks

KEY METRICS
  • Current Structure and Leadership Level of the Medical Information Group
  • Compliance Guidelines and Rules Adhered To for Medical Information Activities
  • Types of Information Shared with Payers and Providers for the Purposes of Compliance
  • Involvement of Medical Information Groups in Different Medical Information Activities
  • Importance of Various Medical Information Activities
  • Sales Revenue per Medical Information Full-Time Employee (FTE)
  • Medical Information Budget as a Percentage of Total Medical Affairs Spend
  • Medical Information FTE as a Percentage of Medical Affairs FTE

SAMPLE KEY FINDINGS
  • Current Structure: Medical Information groups structures are usually either “Centralized or Hybrid” organizations. 84% of participants’ Medical Information groups have either centralized or hybrid structure.
  • Leadership: 69% of the Medical Information groups in the study have director-level leadership. Having high-level leaders illustrates the importance of Medical Information groups.

METHODOLOGY

Best Practices, LLC engaged 26 executives from 25 leading bio-pharmaceutical companies for this benchmarking study. Eleven benchmark participants represent large bio-pharmaceutical organizations, while 8 participants represent medium-sized companies and the remaining benchmark class emerge from small companies. Also 8 companies form a US-only segment, while 19 companies form a Global segment.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Abbvie; Alnylam Pharmaceuticals; Astellas; AstraZeneca; Baxalta; Bayer; Boehringer Ingelheim; CSL Behring; Ferring Pharmaceuticals; Galderma; GW Pharmaceuticals; Incyte; Janssen; Lundbeck; Merck; Novartis; Neurocrine Biosciences; Pierre Fabre Medicament; ProStrakan; Pfizer; Sunovion; Teva Pharmaceutical Industries Ltd; Tillotts Pharma; Upsher-Smith; Xenoport

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.